The Natural Course of Infantile Spinal Muscular Atrophy With Respiratory Distress Type 1 (SMARD1)
- 1 January 2012
- journal article
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 129 (1) , e148-e156
Abstract
Background: Only scarce information is available on the long-term outcome and the natural course of children with infantile spinal muscular atrophy with respiratory distress type 1 (SMARD1) due to mutations in the IGHMBP2 gene. Objective: To describe the natural disease course, to systematically quantify the residual capacities of children with SMARD1 who survive on permanent mechanical respiration, and to identify markers predicting the disease outcome at the time of manifestation. Methods: We conducted a longitudinal study of 11 infantile SMARD1 patients over a mean observational period of 7.8 (SD 3.2) years. Disease-specific features were continuously assessed by using a semiquantitative scoring system. Additionally, we analyzed the residual enzymatic activity of 6 IGHMBP2 mutants in our patients. Results: After an initial rapid decline of the clinical score until the age of 2 years, residual capabilities reached a plateau or even improved. The overall clinical outcome was markedly heterogeneous, but clinical scores at the age of 3 months showed a positive linear correlation with the clinical outcome at 1 year and at 4 years of age. If expressed in an in vitro recombinant system, mutations of patients with more favorable outcomes retained residual enzymatic activity. Conclusions: Despite their severe disabilities and symptoms, most SMARD1 patients are well integrated into their home environment and two thirds of them are able to attend kindergarten or school. This information will help to counsel parents at the time of disease manifestation.Keywords
This publication has 32 references indexed in Scilit:
- SF1 and SF2 helicases: family mattersCurrent Opinion in Structural Biology, 2010
- Spinal Muscular Atrophy Type 1: Prolongation of Survival by Noninvasive Respiratory AidsPediatric Asthma, Allergy & Immunology, 2009
- Biochemical and genetic evidence for a role of IGHMBP2 in the translational machineryHuman Molecular Genetics, 2009
- The Nuclear Factor κB–Activator Gene PLEKHG5 Is Mutated in a Form of Autosomal Recessive Lower Motor Neuron Disease with Childhood OnsetThe American Journal of Human Genetics, 2007
- Mutation of Gene in Spinal Muscular Atrophy Respiratory Distress Type IPediatric Neurology, 2006
- Dilated cardiomyopathy in the nmd mouse: transgenic rescue and QTLs that improve cardiac function and survivalHuman Molecular Genetics, 2005
- Genomic rearrangements at the IGHMBP2 gene locus in two patients with SMARD1Human Genetics, 2004
- Long-Term Observations of Patients with Infantile Spinal Muscular Atrophy with Respiratory Distress Type 1 (SMARD1)Neuropediatrics, 2004
- Transgenic rescue of neurogenic atrophy in the nmd mouse reveals a role for Ighmbp2 in dilated cardiomyopathyHuman Molecular Genetics, 2004
- Molecular Characterization of the Rat Insulin Enhancer-binding Complex 3b2Journal of Biological Chemistry, 1995